Fares Abdelsalam

Fares Abdelsalam

Auto-generated profile, based on publicly available information

Fares Abdelsalam

Medical Research Group of Egypt, Negida Academy, Arlington, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
AAAlaa Abdrabou Abouelmagd
Alaa Abdrabou Abouelmagd
AAAmro Mamdouh Abdelrehim
Amro Mamdouh Abdelrehim
MBMohamed Nabih Bashir
Mohamed Nabih Bashir
FAFares Abdelsalam
Fares Abdelsalam
AMAhmed Marey
Ahmed Marey
MBMohamed Mohamed Belal
Mohamed Mohamed Belal
Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception until May 2024. Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients. We excluded studies on healthy populations, non-English texts, single-arm studies, animal studies, and abstracts. RevMan software (version 5.4) was used for analysis, with subgroup evaluation by dose (4 mg, 8 mg, 12 mg). Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria. Retatrutide significantly reduced body weight (mean difference [MD]: −14.33%), body mass index (MD: −5.38), waist circumference (MD: −10.51 cm), fasting plasma glucose (MD: −23.51 mg/dL), hemoglobin A1c (MD: −0.91%), and systolic and diastolic blood pressure (MD: −9.88 mm Hg and −3.88 mm Hg, respectively), all with P values < 0.00001. No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24). Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile. However, additional large and long-term trials are required to establish these results.

7 May 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ARAhmed Ramzi
Ahmed Ramzi
SMSubhia Maya
Subhia Maya
NBNadeen Balousha
Nadeen Balousha
MAMufreh Amin
Mufreh Amin
RRRovan Ahmed Rouby
Rovan Ahmed Rouby
MSMostafa Ramzi Shiha
Mostafa Ramzi Shiha

15 November 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
ENEman Ayman Nada
Eman Ayman Nada
MEMohamed Abdelhalim Elfagieh
Mohamed Abdelhalim Elfagieh
FAFares Abdelsalam
Fares Abdelsalam
AEAsmaa Ahmed Elrashedy
Asmaa Ahmed Elrashedy
FIFatima Abdulmoain Idres
Fatima Abdulmoain Idres
BHBelal mohamed Mohamed Hamed
Belal mohamed Mohamed Hamed
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell production, with high risk of venous and arterial thrombosis. Mutations in the JAK2 gene, particularly JAK2 V617F, play a central role in its pathogenesis. Ropeginterferon alfa-2b is a novel long-acting interferon showing promise in managing PV through hematologic and molecular control. This study aimed to evaluate the efficacy and safety of Ropeginterferon alfa-2b in patients with PV based on a systematic review and meta-analysis of available clinical trials. A systematic search was conducted across PubMed, Cochrane Library, Web of Science, Google Scholar, and Scopus on May 8, 2025. Randomized controlled trials (RCTs) assessing Ropeginterferon alfa-2b in PV were included. The PRISMA guidelines were followed, and the protocol was registered in PROSPERO (CRD420251051466). Quality assessment was performed using RoB 2.0 and ROBINS-I tools. A random-effects model was applied using R software. Eight studies involving 761 patients were included and only six studies included in single arm meta-analysis with 328 patients. The pooled proportion of complete hematological response at 12 months was 0.63 (95% CI [0.51–0.73]), with high heterogeneity. Reductions in JAK2 V617F allele burden were significant (MD: 26.57, 95% CI [13.49–39.65]). Molecular response was achieved in 25% (95% CI [0.04–0.70]) of patients. The most common adverse events were elevated liver enzymes (AST: 0.28; ALT: 0.32), influenza-like illness (0.11), and anemia (0.09), with unresolved heterogeneity in all outcomes. Ropeginterferon alfa-2b shows promising efficacy in achieving hematological and molecular responses in patients with PV. However, notable heterogeneity and safety concerns, particularly liver-related adverse effects, warrant further investigation in large-scale trials. Graphical Abstract